The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
15-Dec-06
$19.1 billion
Target:
Gallaher Group plc
Acquiror:
Japan Tobacco Inc.
Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
23-Apr-09
$5.7 billion
Target:
Lion Nathan
Acquiror:
Kirin Holdings
Advised Lion Nathan, a leading brewery in Australia, on the sale of its remaining 54% stake to Kirin Holdings, a leading beverage company in Japan
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
09-Sep-13
$2.1 billion
Target:
Lucozade & Ribena brands (owned by GSK)
Acquiror:
Suntory Beverage & Food Ltd
Advised GlaxoSmithKline, the UK listed international pharmaceutical and consumer company, on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
27-Mar-18
$1.6 billion
Target:
Yakult
Acquiror:
Danone
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
09-Jun-20
$1.02 billion
Target:
LIXIL VIVA
Acquiror:
Arcland Sakamoto
Advising Arcland Sakamoto, a leading owner and operator of large home centers, on the acquisition of LIXIL VIVA, a leading owner and operator of large home centers and a listed subsidiary of LIXIL Group, a leading Japanese manufacturer of building and housing materials
09-Sep-05
$1.0 billion
Target:
7-Eleven, Inc.
Acquiror:
Seven-Eleven Japan Co., Ltd
Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd
04-Dec-13
$850 million
Target:
Megapolis Distribution
Acquiror:
Japan Tobacco Inc
Advised Japan Tobacco Inc in connection with the acquisition of a minority stake in Megapolis Distribution B.V., Russia’s leading tobacco distributor
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
06-Jul-12
$730 million
Target:
WMF Württembergische Metallwarenfabrik AG
Acquiror:
Kohlberg Kravis Roberts & Co. L.P.
Provided fairness opinion to the Executive Management Board of WMF in connection with the voluntary public takeover offer by Finedining Capital GmbH, a holding company in the possession of funds managed by Kohlberg Kravis Roberts & Co. L.P.
24-Aug-12
$674 million
Target:
ITX (Mobile Phone Retailing Business)
Acquiror:
Japan Industrial Partners
Advised Japan Industrial Partners, a leading private equity firm in Japan, on the acquisition of mobile phone retailing business from ITX, a mobile phones marketer and distributor in Japan
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
22-Feb-17
$533 million
Target:
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Acquiror:
Saputo Inc.
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
16-Jan-12
$428 million
Target:
Robert Wiseman Dairies PLC
Acquiror:
Unternehmensgruppe Theo Müller
Advised Robert Wiseman Dairies PLC, the UK’s largest processor of fresh milk, on a recommended offer from Unternehmensgruppe Theo Müller S.e.c.s.